Specialty medicines • Bangladesh

Palbocent 125 MG (Palbociclib)

Product Name : Palbocent
Generic Name : Palbociclib
Formulation : Hard Capsule
Available Pack Size : 21 Capsules per box (3 x 7 Blister strip)
Available Strengths : 125 mg
Manufacturer : Incepta Pharmaceuticals Ltd.
Country Of Origin : Bangladesh

Confirm your order

Speak with our team about your prescribed strength, pack size, price and delivery.
Use medicines only as prescribed by your clinician.

Description

Palbocent 125 MG (Palbociclib) is an orally bioavailable, selective, small-molecule inhibitor of cyclin-dependent kinase 4 and cyclin-dependent kinase 6 (CDK4/6) the first CDK4/6 inhibitor class to enter clinical practice that blocks ATP binding at the CDK4/6 kinase active site, preventing cyclin D1–CDK4/6 complex-mediated phosphorylation of the retinoblastoma (Rb) tumor suppressor protein, thereby maintaining Rb in its hypophosphorylated, active, growth-suppressive state, arresting cell cycle progression at the G1-to-S phase transition, and suppressing downstream E2F transcription factor release and DNA synthesis: in estrogen receptor-positive (ER+), HER2-negative breast cancer cells where cyclin D1 overexpression and CDK4/6 hyperactivation drive endocrine therapy resistance this G1 arrest is cytostatic and profoundly synergistic with endocrine therapy, restoring hormonal sensitivity and significantly prolonging progression-free survival, supplied as hard capsules, 125 mg strength, 21 capsules per box (3 × 7 blister strips), and manufactured by Incepta Pharmaceuticals Ltd. in Bangladesh.

 

Palbociclib, the active pharmaceutical ingredient (API) of Palbocent, holds two FDA-approved indications in hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer: (1) in combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women, based on the Phase 3 PALOMA-2 trial demonstrating a median progression-free survival (PFS) of 24.8 months with palbociclib plus letrozole versus 14.5 months with placebo plus letrozole (HR 0.576; 95% CI 0.463–0.718; p<0.0001) the first treatment for this population to exceed a two-year median PFS in a Phase 3 study; and (2) in combination with fulvestrant in women with disease progression following endocrine therapy, based on the Phase 3 PALOMA-3 trial demonstrating a median PFS of 9.5 months with palbociclib plus fulvestrant versus 4.6 months with placebo plus fulvestrant representing a clinically meaningful doubling of progression-free time.

 

The recommended dose of palbociclib is 125 mg (one Palbocent 125 MG hard capsule) orally once daily for 21 consecutive days, followed by 7 days off treatment, completing one 28-day cycle; at this dose, one box of 21 capsules provides exactly one treatment week, and three boxes of Palbocent 125 MG provide one complete 21-day on-treatment period per cycle. Important: Neutropenia is the most frequently reported adverse reaction with palbociclib; Grade 3–4 neutropenia occurred in 66% and 10% of patients, respectively, in PALOMA-2; complete blood count (CBC) with differential must be monitored prior to starting therapy, at the beginning of each cycle, and on Day 15 of the first two cycles, and as clinically indicated; palbociclib should be dose-interrupted or reduced for Grade 3 or higher neutropenia.

 

Febrile neutropenia, including one death due to neutropenic sepsis, has been reported; instruct patients to promptly report fever. Interstitial lung disease (ILD) and pneumonitis, including fatal cases, have been reported; interrupt palbociclib for new or worsening pulmonary symptoms and permanently discontinue for confirmed ILD/pneumonitis. Palbociclib is embryo-fetal toxic; females of reproductive potential must use effective contraception during treatment and for at least 3 weeks after the last dose; males with female partners of reproductive potential must use condoms during treatment and for at least 3 months after the last dose.

 

Palbociclib is primarily metabolized by CYP3A and SULT2A1; strong CYP3A inhibitors increase palbociclib plasma exposure and must be avoided; if a strong CYP3A inhibitor must be co-administered, reduce the palbociclib dose to 75 mg once daily; strong CYP3A inducers substantially decrease palbociclib exposure and must be avoided. Searching for Palbocent 125 MG Palbociclib? Mediaid Pharmacy lists this product across its oncology medicines, breast cancer medicines, and Incepta Pharmaceuticals medicines portfolios and ships it worldwide.

Basic Product Information of Palbocent 125 MG (Palbociclib)

Brand Name Palbocent 125 MG (Palbociclib)
Product Name Palbocent
Generic Name Palbociclib (developmental code PD-0332991; an orally bioavailable, selective, small-molecule inhibitor of cyclin-dependent kinase 4 (CDK4) and cyclin-dependent kinase 6 (CDK6), belonging to the pyridopyrimidine class of CDK inhibitors; palbociclib blocks ATP binding at the CDK4/6 active site, preventing cyclin D1–CDK4/6 complex-mediated phosphorylation of the retinoblastoma (Rb) tumor suppressor protein, arresting the cell cycle at the G1-to-S phase transition and suppressing DNA replication in ER+/HER2- breast cancer cells; the originator brand is Ibrance®, developed and commercialized globally by Pfizer Inc.; initial FDA accelerated approval for ER+/HER2- advanced breast cancer in combination with letrozole: February 3, 2015; FDA regular approval expanded to HR+/HER2- advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy: March 31, 2017; FDA approval in combination with fulvestrant for HR+/HER2- advanced breast cancer following endocrine therapy progression: February 19, 2016)
Drug Class CDK4/6 Inhibitor (Cyclin-Dependent Kinase 4 and 6 Inhibitor); Cell Cycle Inhibitor; Rb Pathway Inhibitor; G1-S Phase Cell Cycle Arrest Agent; Pyridopyrimidine Derivative; Small-Molecule Kinase Inhibitor; Oral Targeted Oncology Agent; HR+/HER2- Breast Cancer Therapy; Endocrine Therapy Sensitizer; Anti-Proliferative Agent; CDK4/6–Cyclin D1 Complex Inhibitor; Retinoblastoma (Rb) Protein Dephosphorylation Inducer
Formulation Hard Capsule (oral administration; must be taken with food palbociclib bioavailability is significantly reduced under fasted conditions; swallow capsules whole, do not crush, open, or chew; one 125 mg capsule is taken as a single once-daily dose, administered at the same time each day for 21 consecutive days; if a dose is missed or vomited, do not take an additional dose for that day resume the next scheduled dose at the regular once-daily time)
Available Strengths 125 mg per hard capsule (Palbocent 125 MG; this is the recommended starting dose of palbociclib 125 mg once daily for 21 days on / 7 days off, in a 28-day cycle; dose reductions for toxicity follow a stepwise protocol: first reduction to 100 mg once daily; second reduction to 75 mg once daily; permanently discontinue if 75 mg once daily is not tolerated; for patients receiving concomitant strong CYP3A inhibitors (if unavoidable), reduce the starting dose to 75 mg once daily; for severe hepatic impairment (Child-Pugh C), reduce the starting dose to 75 mg once daily)
Available Pack Size 21 capsules per box (3 × 7 blister strips); at the recommended starting dose of 125 mg once daily for 21 consecutive days per 28-day cycle, one box of Palbocent 125 MG provides exactly one complete 21-day on-treatment period per cycle; the 7-day off-treatment period in each cycle requires no capsules; three boxes are therefore required per 28-day treatment cycle at the standard dose; the 21-capsule / 3 × 7 blister-strip box format aligns directly with the palbociclib 21-days-on dosing architecture, simplifying dispensing by oncology pharmacies, hospital formularies, and patient access programs managing palbociclib therapy globally
Dosing Schedule Recommended Starting Dose: Palbociclib 125 mg (one Palbocent 125 MG hard capsule) orally once daily with food, for 21 consecutive days followed by 7 days off (28-day cycle), repeated continuously until disease progression or unacceptable toxicity. Indication 1 HR+/HER2- Advanced/Metastatic Breast Cancer, First-Line (PALOMA-2 indication): Palbocent 125 MG once daily (days 1–21 of each 28-day cycle) in combination with letrozole 2.5 mg orally once daily continuously, initiated concurrently; treatment continues until disease progression or unacceptable toxicity. Indication 2 HR+/HER2- Advanced/Metastatic Breast Cancer, Post-Endocrine Therapy Progression (PALOMA-3 indication): Palbocent 125 MG once daily (days 1–21 of each 28-day cycle) in combination with fulvestrant 500 mg administered intramuscularly on Days 1, 15, and 29, and once monthly thereafter; pre/perimenopausal women must also receive concurrent LHRH agonist therapy. Mandatory Baseline Assessment: Complete blood count (CBC) with differential at baseline, at the beginning of each cycle, and on Day 15 of the first two cycles, and as clinically indicated. Dose Reduction for Toxicity (First Reduction): 100 mg once daily. Second Reduction: 75 mg once daily. Permanently discontinue if 75 mg once daily is not tolerated. CYP3A Interaction Dose Adjustments: Avoid concomitant strong CYP3A inhibitors and inducers; if a strong CYP3A inhibitor is unavoidable, reduce palbociclib to 75 mg once daily. Hepatic Impairment: No dose adjustment required for mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment; reduce to 75 mg once daily in patients with severe hepatic impairment (Child-Pugh C). Renal Impairment: No dose adjustment required for mild, moderate, or severe renal impairment (CrCl ≥15 mL/min). All dose modification decisions must be directed by the treating oncologist.
Primary Indications (1) HR+/HER2- Advanced or Metastatic Breast Cancer First-Line Combination with Aromatase Inhibitor (PALOMA-2): Palbociclib 125 mg once daily (21 days on / 7 days off) in combination with letrozole 2.5 mg once daily continuously, as initial endocrine-based therapy in postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer. Based on the Phase 3 PALOMA-2 trial (NCT01740427; n=666): median PFS 24.8 months (palbociclib + letrozole) vs 14.5 months (placebo + letrozole) (HR 0.576; 95% CI 0.463–0.718; p<0.0001) a 71% relative improvement and the first treatment in this population to exceed two years of median PFS in a Phase 3 setting. FDA regular approval: March 31, 2017 (accelerated approval: February 3, 2015).

(2) HR+/HER2- Advanced or Metastatic Breast Cancer Post-Endocrine Therapy Progression, Combination with Fulvestrant (PALOMA-3): Palbociclib 125 mg once daily (21 days on / 7 days off) in combination with fulvestrant 500 mg IM (Days 1, 15, 29, then monthly), in pre/perimenopausal and postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer who have experienced disease progression following prior endocrine therapy. Based on the Phase 3 PALOMA-3 trial (NCT01942135; n=521): median PFS 9.5 months (palbociclib + fulvestrant) vs 4.6 months (placebo + fulvestrant) representing a clinically meaningful doubling of progression-free time and a prolonged time to chemotherapy; OS demonstrated a numerical improvement of approximately 6.9 months favoring palbociclib, though not reaching statistical significance. FDA regular approval: February 19, 2016.

Manufacturer / Brand Incepta Pharmaceuticals Ltd., Country of Origin: Bangladesh (originator molecule and brand Ibrance® developed and commercialized globally by Pfizer Inc.; initial FDA accelerated approval for ER+/HER2- advanced breast cancer + letrozole: February 3, 2015 (PALOMA-1 basis); FDA regular approval for HR+/HER2- advanced breast cancer + aromatase inhibitor (1st-line): March 31, 2017 (PALOMA-2 basis); FDA approval for HR+/HER2- advanced breast cancer + fulvestrant (post-endocrine therapy): February 19, 2016 (PALOMA-3 basis))
Global Supplier Mediaid Pharmacy, Worldwide Shipping Available
Storage Conditions Store below 30°C (86°F). Store in the original blister packaging until dispensing. Protect from moisture and direct light. Keep out of the reach of children.
Key Safety Warnings Neutropenia: The most frequently reported adverse reaction with palbociclib; Grade 3 neutropenia occurred in 66% (PALOMA-2) and 55% (PALOMA-3) of patients, Grade 4 in 10–11%; febrile neutropenia reported in 1.8% across both studies; one death due to neutropenic sepsis observed in PALOMA-3; monitor CBC with differential at baseline, beginning of each cycle, Day 15 of first two cycles, and as clinically indicated; dose interrupt or reduce for Grade 3–4 neutropenia as directed; instruct patients to promptly report any fever. ILD/Pneumonitis: Interstitial lung disease and pneumonitis, including fatal cases, have been reported; interrupt palbociclib for new or worsening respiratory symptoms; permanently discontinue for confirmed ILD/pneumonitis. Embryo-Fetal Toxicity: Palbociclib can cause fetal harm; females of reproductive potential must use effective contraception during treatment and for at least 3 weeks after the last dose; males with female partners of reproductive potential must use condoms during treatment and for at least 3 months after the last dose. CYP3A Drug Interactions: Palbociclib is metabolized primarily by CYP3A; strong CYP3A inhibitors (e.g., clarithromycin, ketoconazole, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole) significantly increase palbociclib plasma exposure; strong CYP3A inducers (e.g., rifampin, carbamazepine, enzalutamide, phenobarbital, phenytoin, St. John’s wort) substantially decrease palbociclib exposure; concomitant use with strong CYP3A inhibitors or inducers must be avoided unless dose adjustment is made as directed by the treating oncologist.
Categories Breast Cancer Medicines, Oncology Medicines, Incepta Pharmaceuticals Medicines

Who is Palbocent 125 MG (Palbociclib) Indicated For?

First, postmenopausal women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer who have not previously received systemic treatment for their advanced disease are the primary candidates for palbociclib in combination with an aromatase inhibitor as initial endocrine-based therapy the PALOMA-2-defined first-line indication for Palbocent, and the indication supported by the most compelling Phase 3 efficacy data for a CDK4/6 inhibitor in the first-line metastatic setting among the original approval data package.

The Phase 3 PALOMA-2 trial (NCT01740427) enrolled 666 postmenopausal women with HR-positive, HER2-negative advanced breast cancer who had no prior systemic therapy for their advanced disease and randomized them 2:1 to palbociclib 125 mg once daily (21 days on / 7 days off) plus letrozole 2.5 mg once daily continuously, versus placebo plus letrozole. The primary endpoint of investigator-assessed PFS was met with a median PFS of 24.8 months in the palbociclib arm versus 14.5 months in the placebo arm (HR 0.576; 95% CI 0.463–0.718; p<0.0001) a statistically significant and clinically meaningful 71% relative improvement in median PFS, and the first time in a Phase 3 study that any treatment for this patient population achieved a median PFS exceeding two years.

PALOMA-2 enrolled patients both with and without prior neoadjuvant or adjuvant endocrine therapy, with or without visceral metastases (excluding patients with symptomatic visceral spread at risk of life-threatening complications), establishing palbociclib as the standard first-line CDK4/6 inhibitor for HR+/HER2- advanced breast cancer in combination with letrozole or any other FDA-approved aromatase inhibitor.

Second, pre/perimenopausal and postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer who have experienced disease progression following prior endocrine therapy are candidates for palbociclib in combination with fulvestrant the PALOMA-3-defined post-endocrine-therapy progression indication for Palbocent. The Phase 3 PALOMA-3 trial (NCT01942135) enrolled 521 women with HR-positive, HER2-negative advanced or metastatic breast cancer (both pre/perimenopausal and postmenopausal) whose disease had progressed on prior endocrine therapy in either the advanced or adjuvant setting and randomized them 2:1 to palbociclib 125 mg once daily (21 days on / 7 days off) plus fulvestrant 500 mg IM (Days 1, 15, 29, then monthly), versus placebo plus fulvestrant; pre/perimenopausal women in both arms received concurrent LHRH agonist goserelin 3.6 mg SC every 28 days.

The primary endpoint of investigator-assessed PFS was met with a median PFS of 9.5 months in the palbociclib arm versus 4.6 months in the placebo arm a clinically meaningful doubling of progression-free time in a heavily pretreated population. PALOMA-3 also demonstrated a prolonged time to first subsequent chemotherapy with palbociclib, an important patient-centered endpoint in a population seeking to delay cytotoxic therapy. The final OS analysis demonstrated a numerical improvement of approximately 6.9 months favoring palbociclib (34.9 months vs 28.0 months), consistent in absolute terms with the PFS benefit demonstrated, though not reaching prespecified statistical significance a limitation acknowledged as reflecting the challenges of demonstrating OS benefit in a disease setting with multiple subsequent active therapies available.

Patients qualifying for the PALOMA-3 indication include those with prior progression on tamoxifen, anastrozole, letrozole, exemestane, or other endocrine agents in either the metastatic or the adjuvant setting, expanding the eligible population substantially beyond postmenopausal patients. Oncology departments managing HR-positive advanced breast cancer treatment protocols and individual patients seeking access to oral targeted oncology medicines can contact Mediaid Pharmacy directly for Palbocent 125 MG availability, pricing, and worldwide delivery.

Global Supplier: Mediaid Pharmacy Worldwide Shipping for Palbocent 125 MG (Palbociclib)

Mediaid Pharmacy is a Dhaka-based supplier of specialty targeted oncology, breast cancer, and oral cancer medicines with worldwide shipping to patients, HR+/HER2- breast cancer oncology departments, CDK4/6 inhibitor treatment programs, first-line and second-line metastatic breast cancer treatment units, hospital pharmacies, oncology day units, patient access programs, and international distributors across all regions. Palbocent 125 MG (Palbociclib), manufactured by Incepta Pharmaceuticals Ltd. in Bangladesh, is supplied as 125 mg hard capsules in 21-capsule boxes (3 × 7 blister strips), with pricing quotations, stock confirmation, full product documentation, and end-to-end international delivery tracking for every order.

The clinical and procurement significance of the 21-capsule / 3 × 7 blister-strip box format is directly tied to palbociclib’s dosing architecture: at the recommended dose of 125 mg once daily for 21 consecutive days per 28-day cycle, one box of Palbocent 125 MG provides exactly one complete 21-day on-treatment period per cycle, and three boxes provide one full cycle’s supply, aligning with standard monthly dispensing and oncology clinic visit schedules used by all oncology pharmacies and hospital formularies managing palbociclib therapy globally.

HR+/HER2- breast cancer oncology departments managing first-line palbociclib + aromatase inhibitor programs; medical oncology teams sourcing palbociclib for second-line fulvestrant combination programs; hospital formulary procurement departments co-sourcing Palbocent with other oral targeted oncology medicines; and individual patients and families seeking access to palbociclib for HR-positive metastatic breast cancer treatment can contact the Mediaid Pharmacy team through WhatsApp, phone, or WeChat for Palbocent 125 MG stock availability, current pricing, and international delivery timelines.

Why Choose Palbocent 125 MG (Palbociclib) from Mediaid Pharmacy?

Palbocent (Palbociclib) from Incepta Pharmaceuticals Ltd. delivers the validated CDK4/6 inhibition mechanism of palbociclib the first CDK4/6 inhibitor to enter clinical practice, with two FDA-approved indications in HR+/HER2- advanced or metastatic breast cancer: in combination with an aromatase inhibitor as initial endocrine-based therapy (PALOMA-2; FDA 2017) and in combination with fulvestrant following endocrine therapy progression (PALOMA-3; FDA 2016) as a precisely formulated 125 mg oral hard capsule in a clinically aligned 21-capsule box providing one complete 21-day on-treatment period per 28-day cycle. Palbociclib is pharmacologically and clinically distinguished within the CDK4/6 inhibitor class by four evidence-based attributes.

First, palbociclib was the first CDK4/6 inhibitor to receive FDA approval and the first to demonstrate that targeting the CDK4/6–cyclin D1–Rb axis in HR+/HER2- advanced breast cancer produces a Phase 3-validated, clinically meaningful PFS benefit exceeding two years in the first-line metastatic setting. The PALOMA-2 median PFS of 24.8 months in the palbociclib plus letrozole arm versus 14.5 months in the placebo plus letrozole arm (HR 0.576; p<0.0001) established the first Phase 3 benchmark exceeding two years of median PFS for any systemic therapy in postmenopausal HR+/HER2- advanced breast cancer, setting the clinical standard against which all subsequent CDK4/6 inhibitors were validated and positioning palbociclib as the reference CDK4/6 inhibitor for first-line HR+/HER2- metastatic breast cancer based on the most mature and extensively reviewed Phase 3 dataset in this drug class.

Second, palbociclib’s unique intermittent dosing schedule 21 days on, 7 days off in a 28-day cycle was specifically engineered to allow bone marrow recovery from hematological toxicity between treatment periods, producing a Grade 3–4 neutropenia rate that, while numerically high at 66–76%, is predominantly asymptomatic, rapidly reversible during the 7-day off period, and associated with a febrile neutropenia rate of only 1.8% across both PALOMA-2 and PALOMA-3 an unprecedented adverse event profile for a drug with Grade 3–4 neutropenia of that magnitude, reflecting the cytostatic and reversible mechanism of CDK4/6-mediated cell cycle arrest rather than the cytotoxic DNA damage of traditional chemotherapy. The 2.5–9.7% treatment discontinuation rate due to adverse events in PALOMA-2 and PALOMA-3 is substantially lower than discontinuation rates reported in comparable Phase 3 trials combining endocrine therapy with biologicals.

Third, palbociclib is effective and approved across both pre/perimenopausal and postmenopausal populations, with PALOMA-3 enrolling patients of any menopausal status (pre/perimenopausal patients received concurrent LHRH agonist therapy), making Palbocent clinically relevant to the full spectrum of patients with HR+/HER2- advanced breast cancer regardless of menopausal status a distinction that reflects the breadth of the hormone receptor-positive breast cancer patient population and the importance of CDK4/6 inhibition as a treatment approach across all age groups.

Fourth, palbociclib is an orally self-administered once-daily hard capsule taken with food for 21 consecutive days per 28-day cycle, enabling complete outpatient management with a dosing schedule that integrates a structured 7-day rest period aligned with standard monthly oncology review visits; patients self-administer one Palbocent 125 MG capsule once daily at the same time each day without the need for infusion visits, IV access, or on-site drug administration, maximizing convenience, adherence, and quality of life across both the first-line and post-endocrine-therapy settings. The 21-capsule box size, providing exactly one 21-day treatment period per cycle, aligns naturally with the palbociclib on-treatment architecture and standard monthly prescription refill cycles.

Palbocent 125 MG is manufactured by Incepta Pharmaceuticals Ltd. and is available through Mediaid Pharmacy in 21-capsule boxes (3 × 7 blister strips). To source the complete range of CDK4/6 inhibitor therapies, HR-positive breast cancer targeted medicines, and oral oncology medicines, visit the Mediaid Pharmacy breast cancer medicines portfolio, the oncology medicines collection, and the Incepta Pharmaceuticals medicines range, and contact the team for a personalized quotation.

Frequently Asked Questions About Palbocent 125 MG (Palbociclib)

What is Palbocent 125 MG (Palbociclib) used for?

Palbocent 125 MG (Palbociclib) is an oral CDK4/6 inhibitor with two FDA-approved indications in hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer. Indication 1: in combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women based on Phase 3 PALOMA-2 (NCT01740427; n=666): median PFS 24.8 months (palbociclib + letrozole) vs 14.5 months (placebo + letrozole) (HR 0.576; 95% CI 0.463–0.718; p<0.0001); FDA regular approval March 31, 2017. Indication 2: in combination with fulvestrant in women with disease progression following endocrine therapy based on Phase 3 PALOMA-3 (NCT01942135; n=521): median PFS 9.5 months (palbociclib + fulvestrant) vs 4.6 months (placebo + fulvestrant); FDA approval February 19, 2016. The recommended dose is 125 mg once daily for 21 consecutive days followed by 7 days off treatment (28-day cycle), taken with food. Palbocent 125 MG (21 capsules per box, 3 × 7 blister strips) is manufactured by Incepta Pharmaceuticals Ltd. in Bangladesh and is available through Mediaid Pharmacy with worldwide shipping.

What is the generic name of Palbocent?

The generic name of Palbocent is palbociclib (developmental code PD-0332991). Palbociclib is an orally bioavailable, selective, small-molecule inhibitor of cyclin-dependent kinase 4 (CDK4) and cyclin-dependent kinase 6 (CDK6), belonging to the pyridopyrimidine class of CDK inhibitors. Palbociclib functions by blocking ATP binding at the CDK4/6 kinase active site, preventing cyclin D1–CDK4/6 complex-mediated phosphorylation of the retinoblastoma (Rb) tumor suppressor protein, maintaining Rb in its hypophosphorylated, growth-suppressive state, and arresting cell cycle progression at the G1-to-S phase transition a mechanism of particular clinical relevance in ER+/HER2- breast cancer cells, where cyclin D1 overexpression and CDK4/6 hyperactivation are both common and directly linked to endocrine therapy resistance. Palbociclib is pharmacologically distinct from other approved CDK4/6 inhibitors (ribociclib, abemaciclib) by its pyridopyrimidine scaffold, its intermittent 21-days-on / 7-days-off dosing schedule (versus continuous daily dosing for abemaciclib), its status as the first CDK4/6 inhibitor to receive FDA approval (February 2015), and its requirement for administration with food (fasted administration significantly reduces bioavailability). The originator brand of palbociclib is Ibrance®, developed and commercialized globally by Pfizer Inc., with first FDA approval on February 3, 2015. Palbocent is manufactured by Incepta Pharmaceuticals Ltd. in Bangladesh and is available as 125 mg hard capsules in 21-capsule boxes (3 × 7 blister strips). Mediaid Pharmacy distributes Palbocent (Palbociclib) globally with worldwide shipping to patients, breast cancer oncology departments, hospital pharmacies, and HR-positive breast cancer treatment programs worldwide.

What is the difference between palbociclib, ribociclib, and abemaciclib for HR+/HER2- breast cancer?

Palbociclib (Palbocent), ribociclib (Kisqali), and abemaciclib (Verzenio) are all oral CDK4/6 inhibitors approved in HR+/HER2- advanced or metastatic breast cancer, but differ in molecular scaffold, dosing schedule, CDK selectivity, breadth of approvals, and demonstrated overall survival data. Palbociclib is a pyridopyrimidine CDK4/6 inhibitor taken at 125 mg once daily for 21 days on / 7 days off in 28-day cycles with food; it was the first CDK4/6 inhibitor to receive FDA approval (2015), demonstrated a median PFS of 24.8 months in PALOMA-2 and 9.5 months in PALOMA-3, and is approved in two settings first-line + aromatase inhibitor and post-endocrine progression + fulvestrant; OS data from PALOMA-2 and PALOMA-3 showed numerical but non-statistically-significant improvements. Ribociclib is a pyrrolopyrimidine CDK4/6 inhibitor taken at 600 mg once daily for 21 days on / 7 days off with or without food; it is approved in three settings across pre/peri/postmenopausal women and has demonstrated statistically significant OS benefit in multiple Phase 3 trials (MONALEESA-2, MONALEESA-3, MONALEESA-7). Abemaciclib is a benzimidazole CDK4/6 inhibitor with the highest selectivity for CDK4 over CDK6 in the class, taken at 150 mg twice daily continuously (no scheduled rest period) with or without food; it is the only CDK4/6 inhibitor approved in the early breast cancer adjuvant setting (monarchE) for high-risk, node-positive HR+/HER2- early breast cancer, as well as in advanced settings including monotherapy; it is associated with higher rates of diarrhea and venous thromboembolism due to its continuous dosing and additional CDK inhibition activity. Palbociclib is specifically distinguished by its first-in-class regulatory history, its extensively characterized safety profile across the PALOMA program, and its direct compatibility with the standard 21-day on-treatment period reflected in the Palbocent 21-capsule box format. Visit the Mediaid Pharmacy breast cancer medicines collection for the complete HR-positive targeted therapy portfolio.

What are the side effects of Palbocent (Palbociclib)?

The most clinically significant adverse effect of palbociclib is neutropenia, with serious but manageable risks from febrile neutropenia, ILD/pneumonitis, and embryo-fetal toxicity. Neutropenia is the most frequently reported adverse reaction, occurring in 80% of patients in PALOMA-2 and 83% in PALOMA-3 (all grades); Grade 3 neutropenia occurred in 66% (PALOMA-2) and 55% (PALOMA-3) of patients, Grade 4 in 10–11%; the majority of neutropenia events are asymptomatic and reversible during the 7-day off-treatment period; febrile neutropenia, however, was reported in 1.8% of patients across both studies, and one death due to neutropenic sepsis was observed in PALOMA-3; CBC with differential must be monitored at baseline, beginning of each cycle, and Day 15 of the first two cycles, and as clinically indicated; palbociclib must be dose-interrupted or reduced for Grade 3–4 neutropenia. Infections occurred in 60% (PALOMA-2) and 47% (PALOMA-3) of patients receiving palbociclib; Grade ≥3 infections occurred in 7% in PALOMA-2. Leukopenia occurred in 39% (PALOMA-2) and 53% (PALOMA-3) of patients. Fatigue occurred in 37% (PALOMA-2) and 38% (PALOMA-3) of patients. Nausea occurred in 35% (PALOMA-2) and 34% (PALOMA-3). Alopecia occurred in 33% of patients in PALOMA-2. Anemia occurred in 24–30% of patients. ILD/Pneumonitis, including fatal cases, has been reported; interrupt palbociclib for new or worsening respiratory symptoms and permanently discontinue for confirmed ILD/pneumonitis. Embryo-fetal toxicity: palbociclib can cause fetal harm; females of reproductive potential must use effective contraception during treatment and for at least 3 weeks after the last dose; males must use condoms during treatment and for at least 3 months after the last dose. Always establish baseline CBC with differential and a pregnancy test (in females of reproductive potential) before initiating Palbocent under the supervision of an experienced oncologist.

How is Palbocent 125 MG (Palbociclib) administered?

Palbociclib (Palbocent 125 MG) is administered orally, once daily, at the same time each day, with food administration with food is required because palbociclib bioavailability under fasted conditions is significantly reduced and inconsistent. The recommended starting dose is 125 mg (one Palbocent 125 MG hard capsule) orally once daily with food, for 21 consecutive days followed by 7 days off treatment, completing one 28-day cycle; this schedule is repeated continuously until disease progression or unacceptable toxicity. At each dose time, one capsule is taken; swallow capsules whole do not crush, open, or chew palbociclib capsules. If a dose is missed or vomited, do not take an additional dose for that day resume the next scheduled dose at the regular once-daily time. In the PALOMA-2 indication, palbociclib is initiated concurrently with letrozole 2.5 mg orally once daily continuously; in the PALOMA-3 indication, palbociclib is initiated concurrently with fulvestrant 500 mg IM (Days 1, 15, 29, then monthly); pre/perimenopausal patients in the fulvestrant combination setting must also receive concurrent LHRH agonist therapy. Mandatory safety monitoring before initiating and during treatment includes: CBC with differential (baseline, beginning of each cycle, Day 15 of first two cycles, and as clinically indicated); pregnancy test in females of reproductive potential (baseline). Dose reductions follow a stepwise protocol: first reduction to 100 mg once daily; second reduction to 75 mg once daily; permanently discontinue if 75 mg once daily is not tolerated. All dosing modifications must be directed by the treating oncologist.

Is Palbocent (Palbociclib) safe during pregnancy or while breastfeeding?

Palbocent (Palbociclib) can cause fetal harm and is contraindicated during pregnancy based on its mechanism of action and animal reproductive toxicology findings. Inhibition of CDK4/6-mediated cell cycle progression by palbociclib disrupts the rapid cellular proliferation required for normal embryonic organogenesis and fetal tissue growth; animal studies demonstrated embryo-fetal lethality and malformations. Females of reproductive potential must use effective contraception during palbociclib treatment and for at least 3 weeks after the last dose. Males with female partners of reproductive potential must use condoms during palbociclib treatment and for at least 3 months after the last dose based on the potential for genotoxicity. There are no data on the presence of palbociclib or its metabolites in human breast milk; because of the potential for serious adverse reactions in a breastfed infant, breastfeeding is not recommended during palbociclib treatment and for at least 3 weeks after the last dose. Verify pregnancy status with a serum or urine pregnancy test before initiating Palbocent in all females of reproductive potential. Palbociclib may impair male fertility based on animal reproductive toxicology data; male patients should discuss fertility preservation options (including sperm banking) with the treating oncologist before initiating therapy. Discuss all aspects of reproductive planning, fertility counseling, and contraceptive requirements with the treating oncologist before starting palbociclib therapy.

Can I order Palbocent 125 MG (Palbociclib) online with worldwide shipping?

Yes. Mediaid Pharmacy supplies Palbocent 125 MG (Palbociclib), hard capsules, 21 capsules per box (3 × 7 blister strips), manufactured by Incepta Pharmaceuticals Ltd. in Bangladesh, to patients, HR+/HER2- breast cancer oncology departments, CDK4/6 inhibitor therapy programs, first-line and post-endocrine-progression metastatic breast cancer treatment units, hospital pharmacies, oncology day units, patient access programs, and healthcare providers globally. Contact Mediaid Pharmacy via WhatsApp, phone, or WeChat at +8801773428128, or email info@mediaidpharmacy.com for pricing, current stock availability, shipping options, and international delivery details for your country.

Order Palbocent 125 MG (Palbociclib) with Worldwide Shipping

Phone / WhatsApp / WeChat: +8801773428128  |  Email: info@mediaidpharmacy.com

Message on WhatsApp

Reviews

There are no reviews yet.

Be the first to review “Palbocent 125 MG (Palbociclib)”

Your email address will not be published. Required fields are marked *